Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Psychopharmacology (Berl). 2014 Apr 30;231(21):4231–4240. doi: 10.1007/s00213-014-3566-6

Table 4.

[11C]NNC112 BPND by Diagnostic Group for PFCa and Striatal ROIs

ROI Controls (n=21) SPD (n=18) pb
PFC:
 DLPFC 1.35 ± 0.22 1.28 ± 0.27 0.369
 MPFC 1.40 ± 0.24 1.28 ± 0.25c 0.172
 OFC 1.40 ± 0.34 1.39 ± 0.30 0.960

Striatal:
 VST 2.50 ± 0.49 2.78 ± 0.44 0.064
 preDCA 2.90 ± 0.59 2.94 ± 0.45 0.792
 preDPU 3.08 ± 0.65 3.14 ± 0.53 0.772
 postCA 2.19 ± 0.41 2.20 ± 0.48 0.969
 postPU 2.96 ± 0.60 2.98 ± 0.50 0.885
 whole STR 2.86 ± 0.54 2.94 ± 0.46 0.618

Note. Mean ± Standard Deviation (observed).

STR=striatum; see Table 2 for other abbreviations.

a

BPND values for all PFC (but not striatal) ROIs were adjusted to correct for partial volume effects (PVE); see text.

b

Group comparisons of the estimated marginal means derived from linear mixed modeling (see text) with the exception of the composite whole STR; for this region, an independent-samples t-test was used.

c

n=17: One SPD participant’s values were excluded due to excessive noise in the VT measurement.

HHS Vulnerability Disclosure